Participating Companies

Abliva Ab [ABLI:ST] SKr142 MM MCap
Fo­cused on rare and se­vere pri­mary mi­to­chon­drial dis­eas­es (PMD). KL1333, a NAD+ reg­u­la­tor, to ac­cel­er­ate in­to piv­o­tal studies in 2H21 based on pos­i­tive FDA feed­back; ini­tial re­sults from Ph1b in PMD pa­tients exp. in 1Q21. NV354, an en­er­gy re­place­ment ther­a­py for Leigh Syn­drome, in IND-en­abling studies. [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] $32 MM MCap
Launched DSU­VIA (sufen­tanil sublin­gual tablet 30 mcg) in the US in 2019 for acute pain se­vere enough to re­quire opi­oid anal­gesic (adult pa­tients in cer­ti­fied med­i­cal­ly su­per­vised health­care sett­ings). Al­so de­vel­op­ing Za­lvi­so (Ph 3 com­plet­ed) in the US as an in­no­va­tive pa­tient-con­trolled anal­ge­sia sys­tem for mod­er­ate-to-se­vere acute pain in med­i­cal­ly su­per­vised sett­ings. [more in­for­ma­tion]
Achilles Therapeutics
cNeT (clo­n­al neoanti­gen) pro­cess builds on TILs, com­bined with abil­i­ty to iden­ti­fy pt-spe­cif­ic clo­n­al neoanti­gens and gen­er­ate per­so­n­al­ized T-cell ther­a­pies. Sep19 GBP100 mil­lion Se­ries B w/ RA, Syn­co­na, For­bion, In­vus, Per­cep­tive + Red­mile. [more in­for­ma­tion]
Adrenomed AG
Pre­ci­sion medicine, car­dio­vas­cu­lar and Sep­sis, Adre­cizumab Ph 2, bio­mark­er-guid­ed, mon­o­clo­n­al anti­body for sep­tic shock; fi­nal da­ta re­leased late Novem­ber: Ear­ly ap­pli­ca­tion of Adre­cizumab leads to a rapid and sta­tis­ti­cal­ly sig­ni­f­i­cant im­prove­ment of fluid bal­ance, sys­temic or­gan func­tion and > 50% rel­a­tive re­duc­tion of all cause mor­tal­i­ty af­ter 28 days and 90 days com­pared to place­bo on top of SoC. [more in­for­ma­tion]
Affibody
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod® plat­forms. Lead can­di­date ABY-035 is an IL-17 with mul­ti­ple Ph 2 pro­grams (PSO OLE PsA, axS­pA, uvei­tis). Pos­i­tive Ph2 52wk da­ta in pso­ri­a­sis with 2-yr OLE da­ta ex­pect­ed in 2H21. Ph2 in­ter­im da­ta for uvei­tis ex­pect­ed in 2022. AB-251 is a di­ag­nos­tic imag­ing pro­gram that is di­rect­ed pri­mar­i­ly to­wards me­tastat­ic breast can­cer. $81M raised to date. [more in­for­ma­tion]
Affimed N.V. [AFMD] $415 MM MCap
NK cell en­gager AFM13 (CD30/CD16A) en­rolling in a Phase 2 reg­is­tra­tion study in CD30-pos­i­tive pe­ripher­al T cell lym­pho­ma and an in­vesti­ga­tor-spon­sored study by MDACC of AFM13 com­bined with al­lo­gene­ic NK cells in re­lapsed/re­frac­to­ry CD30-pos­i­tive lym­pho­ma. [more in­for­ma­tion]
AM-Pharma B.V.
Raised $195M in equi­ty and debt in 2019/2020 af­ter re­sults from Ph 2 in 300+ pts de­mon­s­trat­ed ro­bust sig­ni­f­i­cant im­prove­ment of 40%+ OS in re­cAP group. TL safe­ty & fu­til­i­ty anal­y­sis on first 400 pts Q1 2022. Ex­pects to com­plete tgt en­roll­ment & an­nounce pri­mary end­point da­ta of 28-day all-cause mor­tal­i­ty in 2023, or as ear­ly as 2022 based on in­ter­im anal­y­s­es. [more in­for­ma­tion]
Amarin Corporation [AMRN] $734 MM MCap
Com­mer­cial­iz­ing Vas­ce­pa, the first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from RE­DUCE-IT CV Out­comes trial at AHA. First 9mo rev’s of 2020 ~$450M. [more in­for­ma­tion]
Apexigen
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
Aptorum Group [APM] $47 MM MCap
Hong Kong based, US list­ed com­pany fo­cused on gen­er­at­ing late stage clin­i­cal can­di­dates by de­vel­op­ing al­ready ap­proved drugs for new or­phan in­di­ca­tions, as well as in­fec­tious dis­eas­es. [more in­for­ma­tion]
Arcellx [ACLX] $785 MM MCap
A clin­i­cal-stage biotech­nol­o­gy com­pany rei­magin­ing cell ther­a­py by en­gi­neer­ing in­no­va­tive im­munother­a­pies for pa­tients with can­cer and other in­cur­able dis­eas­es. Ar­cel­lx's lead prod­uct can­di­date, CART-dd­BC­MA, is be­ing de­vel­oped for the treat­ment of re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma (r/r MM) in an on­go­ing Phase 1 study. Ar­cel­lx is al­so ad­vanc­ing its dos­able and con­trol­lable CAR-T ther­a­py, ARC-SparX, in­to the clin­ic through two pro­grams: ACLX-001 in r/r MM and ACLX-002 in re­lapsed or re­frac­to­ry acute mye [more in­for­ma­tion]
AsclepiX Therapeutics
Oph­thal­mol­o­gy com­pany us­ing com­pu­ta­tio­n­al bi­ol­o­gy to iden­ti­fy po­tent pep­tide reg­u­la­tors of vas­cu­lar home­os­ta­sis. The lead clin­i­cal can­di­date, in­te­grin reg­u­lat­ing pep­tide AX­T107 (ger­sizan­gi­tide), has a nov­el mech­anism of ac­tion that in­hibits neo­vas­cu­lariza­tion, re­duces vas­cu­lar perme­a­bil­i­ty and sup­press­es in­flam­ma­tion. In June 2020, Per­cep­tive Xon­toge­ny Ven­ture Fund led the $35 mil­lion Se­ries A fi­nanc­ing with par­ti­ci­pa­tion from ex­ist­ing in­ves­tors Rapha Cap­i­tal Ma­n­age­ment and Bar­er & Son Cap­i­tal. [more in­for­ma­tion]
AxoGen [AXGN] $364 MM MCap
Glob­al lead­er in de­vel­op­ment and mar­ket­ing of in­no­va­tive sur­g­i­cal so­lu­tions for the pe­ripher­al nerve in­jury mar­ket. Gui­dance for 2021 rev­enue is $127M-$129M with ex­pect­ed 2021 Gross Mar­gin re­main­ing above 80%. Lead prod­uct Avance Nerve Graft is a pro­cessed, hu­man al­lo­graft for bridg­ing nerve gaps of up to 70 mm. [more in­for­ma­tion]
Bellus Health [BLU] $1,001 MM MCap
BEL­LUS Health is de­vel­op­ing nov­el ther­a­peu­tics for the treat­ment of chron­ic cough and other hy­persen­si­ti­za­tion-re­lat­ed di­s­or­ders. BEL­LUS' lead prod­uct can­di­date, BLU-5937, is be­ing de­vel­oped for the treat­ment of chron­ic cough (Phase IIb SOOTHE pre-planned in­ter­im in Sept. 2021; to­p­line read­out in 4Q21) and chron­ic pru­ri­tus (Phase II BLUEPRINT read­out 4Q21). [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr979 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) in four com­pany-spon­sored trials. [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] $10,260 MM MCap
Com­mer­cial-stage, fo­cused on neu­ro­log­i­cal & neu­ropsychi­a­tric dis­eas­es; CGRP re­cep­tor an­ta­g­on­ist, glu­ta­mate mo­d­u­la­tion, and MPO plat­forms. NURTEC® ODT ap­proved 1Q20 acute treat­ment of mi­graine and 1Q21 pre­ven­tive treat­ment of mi­graine; $136m 3Q21 rev­enues. [more in­for­ma­tion]
BioShin
Whol­ly owned sub­si­diary of Bio­haven Phar­ma­ceu­ti­cals. Shang­hai-based, led by ex-BMY ex­ec and Bio­haven’s Chief of Corp Strat­e­gy & BD, Don­nie Mc­Grath, Bioshin aims to de­vel­op and com­mer­cial­ize Bio­haven’s late-stage mi­graine and neu­rol­o­gy port­fo­lio in Chi­na and other APAC mar­kets. [more in­for­ma­tion]
BioXcel Therapeutics, Inc. [BTAI] $348 MM MCap
BX­CL501 (sublin­gual dexmede­to­mi­dine): Met pri­mary, key se­condary and ex­plo­ra­to­ry end­points in two piv­o­tal Phase 3 trials for the for the acute treat­ment of ag­i­ta­tion in pa­tients with schi­zophre­nia (SERENI­TY I) and bipo­lar di­s­or­der (SERENI­TY II). Phase 1b/2 trial (TRAN­QUIL­I­TY) on­go­ing for the acute treat­ment of ag­i­ta­tion as­so­ci­at­ed with ge­ri­a­tric de­men­tia. [more in­for­ma­tion]
CalciMedica
Fo­cused on CRAC chan­nel for the treat­ment of acute and se­vere in­flam­ma­to­ry dis­eas­es. CalciMed­i­ca’s lead com­pound Aux­o­ra has de­liv­ered promis­ing Phase 2 re­sults in se­vere COVID-19 pneu­mo­nia and acute pan­cre­ati­tis. A Phase 2/3 clin­i­cal trial of Aux­o­ra in up to 400 pa­tients with se­vere COVID-19 pneu­mo­nia is on­go­ing, and a Phase 2b trial of Aux­o­ra in pa­tients with acute pan­cre­ati­tis and a dose es­ca­lat­ing phase 2 study in ven­ti­lat­ed ARDS pa­tients with COVID-19 and other pneu­mo­nia are ex­pect­ed to com­mence soon. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] $41 MM MCap
Launched EVOMELA® (mel­pha­lan for in­jec­tion, mul­ti­ple myelo­ma) in Au­gust '19, on­ly mel­pha­lan com­mer­cial­ly avai­l­able in Chi­na: $7.1M 2Q21 rev­enues/guid­ing FY 2020 of over 80% growth. Co-com­mer­cial as­set CNCT-19/CD19 CAR-T (part­nered w/ Ju­ven­tas): on­go­ing Ph 2 trials in B-NHL and B-ALL. Dosed 1st pa­tient in Ph 1 study for CID-103 (an­ti-CD38 mAb) in EU in June 2021. [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] $707 MM MCap
Ca­t­alyst's New Drug Ap­pli­ca­tion for FIR­DAPSE® (am­i­fam­pri­dine) Tablets 10 mg for the treat­ment of adults with Lam­bert-Ea­ton myas­thenic syn­drome ("LEMS") was ap­proved in 2018 by the U.S. Food & Drug Ad­min­is­tra­tion ("FDA"), and FIR­DAPSE is com­mer­cial­ly avai­l­able in the Unit­ed States as a treat­ment for adults with LEMS. Fur­ther, Ca­na­da's na­tio­n­al health­care reg­u­la­to­ry agen­cy, Health Ca­na­da, has ap­proved the use of FIR­DAPSE for the treat­ment of adult pa­tients in Ca­na­da with LEMS. [more in­for­ma­tion]
Celularity [CELU] $514 MM MCap
Celu­lar­i­ty, head­quar­tered in Florham Park, NJ, is a clin­i­cal-stage biotech­nol­o­gy com­pany fo­cus­ing on cel­lu­lar medicine by de­vel­op­ing off-the-shelf pla­cen­tal-de­rived al­lo­gene­ic cell ther­a­pies. Celu­lar­i­ty has a her­i­tage as a former cell-ther­a­py busi­ness unit of Cel­gene. [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia, astig­ma­tism, my­opia, my­opia pro­gres­sion) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Om­ni­fo­cal con­tact lens pres­by­opia 510k sub­mis­sion and my­opia pro­gres­sion clin­i­cal da­ta in 2H2022. Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
CureVac AG [CVAC] $2,637 MM MCap
Ger­man mR­NA com­pany with a di­ver­si­fied pipe­line; Ph 2a trial on­go­ing with COVID-19 vaccine can­di­date, CVn­CoV. Glob­al Ph 2/3 trial en­rolling ap­prox. 36,500 par­ti­ci­pants with re­sults ex­pect­ed 1Q21. Three other pro­grams in Ph 1: CV8102 (cu­ta­neous me­lano­ma, ade­noid­cys­tic car­ci­no­ma, squa­mous cell can­cer of skin, head & neck), CV9202 (NS­CLC) and CV7202 (Ra­bies). mR­NA-based anti­body de­liv­ery deal with Genmab (Dec'19). Other strate­g­ic part­n­er­ships in­clude GSK and CRIS­PR Tx. [more in­for­ma­tion]
Enko Chem
The com­pany spe­cial­izes in dis­cov­er­ing small molecules for the con­trol of agri­cul­tu­r­al­ly im­por­tant pests, herbs and fun­gus that da­m­age the crop by pro­duc­ing tox­ic com­pounds and de­crease the qual­i­ty of the crop, en­abling farm­ers to max­i­mize re­source ef­fi­cien­cy and elim­i­nate or min­i­mize prod­uct hazards to cre­ate durable pro­grams for agri­cul­ture pro­duc­tiv­i­ty. [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] $115 MM MCap
Fo­cused on de­vel­op­ing nov­el ther­a­pies for the treat­ment of pros­tate can­cer. ES­SA’s lead clin­i­cal can­di­date, EPI-7386 is an in­vesti­ga­tio­n­al, high­ly-se­lec­tive, oral, small molecule in­hibi­tor of the N-ter­mi­nal do­main of the an­dro­gen re­cep­tor, with Ph 1 monother­a­py da­ta ex­pect­ed in 1H 2022. The com­pany has al­so estab­lished clin­i­cal col­lab­o­ra­tions with JNJ, Astel­las, and Bay­er. [more in­for­ma­tion]
Exicure [XCUR] $16 MM MCap
Cavro­toli­mod (AST-008) in Ph2 trials for pa­tients with Merkel Cell Car­ci­no­ma and Cu­ta­neous Squa­mous Cell Car­ci­no­ma, with Ph1b da­ta pre­sent­ed at AACR 2020. XCUR-FXN in pre­clin­i­cal de­vel­op­ment for pa­tients with Frie­dreich's Ataxia, us­ing ge­net­i­cal­ly tar­get­ed SNA ther­a­pies to re­move FXN tran­scrip­tion block­age. [more in­for­ma­tion]
Faraday Pharmaceuticals
Chron­ic and acute agents to pre­vent car­di­ac and skele­tal mus­cle loss by mo­d­u­lat­ing neu­ro­hu­mo­ral path­ways and res­tor­ing metabolic flex­i­bil­i­ty: lead can­di­date FDY-5301 Ph 3 ready for reper­fu­sion in­jury fol­low­ing heart at­tack (AMI). $57M raised to date from Arch Ven­ture Part­n­ers, Po­laris Part­n­ers, WRF, Os­age [more in­for­ma­tion]
Galera Therapeutics [GRTX] $39 MM MCap
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cus­ing on trans­form­ing ra­dio­ther­a­py in can­cer. Fi­nal da­ta with 1 year+ fol­low up on all pa­tients for GC4419 in pan­cre­at­ic can­cer an­nounced in 3Q21. To­p­line da­ta from GC4711 in NS­CLC ex­pect­ed in 1H22. To­p­line da­ta from GC4711 in NS­CLC ex­pect­ed in 1H22. [more in­for­ma­tion]
GENFIT SA [GNFT] $167 MM MCap
Ipsen li­censed lead can­di­date EL­A­TIVE (ela­fi­branor) for &eu­ro;120M up­front pay­ment, up to &eu­ro;360M in po­ten­tial mile­s­tones, and dou­ble-dig­it roy­al­ties (tiered up to 20%). See Phase 3 EL­A­TIVE en­roll­ment com­ple­tion in 1Q22 and Phase 1 clin­i­cal da­ta for ni­ta­zox­anide (acute chron­ic liv­er fail­ure) by 3Q22 [more in­for­ma­tion]
Geron Corporation [GERN] $532 MM MCap
Fo­cused on the de­vel­op­ment and po­ten­tial com­mer­cial­iza­tion of a first-in-class telom­erase in­hibi­tor, ime­tel­s­tat, in myeloid he­ma­to­log­ic ma­lig­nan­cies. Geron is cur­rent­ly con­duct­ing two on­go­ing reg­is­tra­tion-en­abling Ph 3 clin­i­cal trials: (i) IMerge Phase 3 in Low or In­ter­me­di­ate-1 risk myelodys­plas­tic syn­dromes, or low­er risk MDS, and (ii) IM­pactMF in In­ter­me­di­ate-2 or High-risk myelo­fi­bro­sis, or re­frac­to­ry MF. Geron ex­pects top-line re­sults for IMerge Phase 3 to be avai­l­able at the be­gin­n­ing of Jan­uary 2023. [more in­for­ma­tion]
HaemaLogiX
Pro­pri­e­tary, dif­fer­en­ti­at­ed B cell tar­gets en­gaged via anti­body and CAR-T pro­grams Kap­paMab & Lamb­daMab tar­get ac­ti­vat­ed plas­ma cell anti­gens (KMA/LMA); Kap­paMab plus RevDex vs. RevDex Ph 2b in MM, da­ta 1H20; Kap­pa CAR-T Ph 1 Q120 in MM; Ca­pac­i­ty for du­al-tar­get­ing via CD-19, BC­MA, etc; Lamb­daMab in pre­clin­i­cal for amy­loi­do­sis [more in­for­ma­tion]
Hangzhou Chance Pharmaceuticals
Chance fo­cus­es on in­ha­la­tion prod­ucts with pro­pri­e­tary tech­nolo­gies. [more in­for­ma­tion]
Heidelberg Pharma AG [HPHA:DB] €163 MM MCap
AT­AC plat­form to de­vel­op nov­el can­cer treat­ments with a unique mode of ac­tion killing both in­ac­tive and di­vid­ing can­cers cells and over­com­ing tu­mor re­sis­tance mech­anisms. Lead prod­uct HDP-101, for blood can­cer, is ex­pect­ed to start clin­i­cal dev' end of 2021. Out-li­cens­ing the AT­AC tech­nol­o­gy us­ing the part­n­ers’ anti­bodies to cre­ate new AT­ACs and ex­pect long term in­come streams and ear­ly tech­nol­o­gy vali­da­tion. [more in­for­ma­tion]
Humanigen Inc. [HGEN] $136 MM MCap
re­sults of NIH Phase 2/3 study in COVID that may serve as ba­sis for EUA, BLA, or both in the U.S. ini­ti­a­tion and in­ter­im as­sess­ment of Phase 2/3 trial for pre­ven­tion/treat­ment of acute GVHD, ini­ti­a­tion of Phase 3 with CAR-T and pre­sen­ta­tion of top-line da­ta from some pa­tients at ASH 2022. [more in­for­ma­tion]
Immatics NV [IMTX] $539 MM MCap
Im­mat­ics com­bines the dis­cov­ery of true tar­gets for can­cer im­munother­a­pies with the de­vel­op­ment of the right T cell re­cep­tors with the goal of en­abling a ro­bust and spe­cif­ic T cell re­sponse against th­ese tar­gets. We are com­mitt­ed to de­liv­er­ing the pow­er of T cells and to un­lock­ing new av­enues for pa­tients in their fight against can­cer. [more in­for­ma­tion]
Impact Therapeutics Inc
IM­PACT and Jun­shi Bio­s­ciences estab­lished a 50:50 joint ven­ture that fo­cus­es on the de­vel­op­ment and com­mer­cial­iza­tion of Se­na­parib in Chi­na. The JV is cur­rent­ly con­duct­ing a Phase II piv­o­tal study and a Phase III study of Se­na­parib in ovarian can­cer third-line treat­ment and first-line main­te­nance treat­ment in Chi­na. [more in­for­ma­tion]
IN8bio, Inc. [INAB] $42 MM MCap
First com­pany to ad­vance ge­net­i­cal­ly-mod­i­fied gam­ma-del­ta T cells in­to clin­i­cal trials with its Del­tEx Plat­form, based on ex-vi­vo ex­pand­ed and ac­ti­vat­ed gam­ma-del­ta T cells. Two in­vesti­ga­tor-ini­ti­at­ed Phase 1 clin­i­cal trials are un­der­way for lead prod­uct can­di­dates: INB-200 for new­ly di­ag­nosed glioblas­to­ma and INB-100 for acute leukemia. [more in­for­ma­tion]
Inozyme Pharma [INZY] $202 MM MCap
Lead can­di­date INZ-701 is an en­zyme re­place­ment ther­a­py de­signed to treat cal­ci­fi­ca­tion di­s­or­ders of the cir­cu­la­to­ry sys­tem, bone and kid­ney for which in­suf­fi­cient treat­ment op­tions cur­rent­ly ex­ist. ENP­P1 and ABC­C6 de­fi­cien­cy Phase 1/2 ini­ti­a­tions ex­pect­ed H1'2021 with re­sults H2'2021. [more in­for­ma­tion]
Invetx
In­vetx is build­ing the world’s pre­mi­er biotech­nol­o­gy plat­form for pro­tein-based ther­a­peu­tics in an­i­mal health to trans­form stan­dards of care in ve­t­eri­nary medicine. The In­vetx team of high­ly ex­pe­ri­enced R&D lead­ers from both hu­man biotech and an­i­mal health is sup­port­ed by best-in-class biotech­nol­o­gy part­n­ers and an ex­ten­sive net­work of in­dus­try ex­perts, ve­t­eri­nary sci­en­tists and clini­cians. In­vetx is a pri­vate com­pany head­quar­tered in Bos­ton, Mas­sachusetts. [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] $1,726 MM MCap
De­vel­op­ing nov­el can­cer im­munother­a­pies based on tu­mor in­fil­trat­ing lym­pho­cytes (TIL) for the treat­ment of solid tu­mors. TIL ther­a­py is a high­ly per­so­n­al­ized ap­proach in which pa­tients re­ceive a one-time treat­ment with their own ex­pand­ed and re­ju­ve­nat­ed T-cells to treat can­cer. BLA ex­pect­ed in 1H22 fol­low­ing com­ple­tion of piv­o­tal study of Li­fileu­cel/LN-144 for treat­ment of Me­lano­ma. [more in­for­ma­tion]
ISA Pharmaceuticals BV
is an im­munother­a­py com­pany de­vel­op­ing ra­tio­n­al­ly de­signed, ful­ly syn­thet­ic im­munother­a­peu­tics against can­cer and per­sis­tent vi­ral in­fec­tions. The Com­pany has built a pro­pri­e­tary im­munother­a­py plat­form based on the Syn­thet­ic Long Pep­tide (SLP®) con­cept and AM­PLI­VANT®tech­nol­o­gy. [more in­for­ma­tion]
Junshi Biosciences [1877.HK]
Has a di­ver­si­fied R&D pipe­line com­pris­ing over 21 drug can­di­dates with ther­a­peu­tic ar­eas cov­er­ing can­cer, metabolic, au­toim­mune, neu­ro­log­i­cal, and in­fec­tious dis­eas­es. Lead can­di­date, Tori­pal­imab (JS001), reached over 1B RMB in sales, and ex­pand­ed in­di­ca­tions in­to na­sopha­ryn­geal car­ci­no­ma/urothe­lial car­ci­no­ma. Other prod­uct types in­clude mon­o­clo­n­al anti­bodies, fu­sion pro­teins, anti­body-drug con­ju­gates, and small molecule drugs. With a com­bined 33,000L fer­men­ta­tion ca­pac­i­ty in two GMP-fa­cil­i­ties at Shang­hai [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] $1,696 MM MCap
Aug 30 PD­U­FA da­ta for belu­mo­sudil (cGVHD) fol­low­ing pos­i­tive pri­mary anal­y­sis re­sults (May 2020); ob­served ORRs of 73% and 74% in 200mg QD and 200mg BID arms, re­spec­tive­ly. Ini­ti­at­ing 12-15 pt open-la­bel Ph 2 in pa­tients w dif­fuse cu­ta­neous sys­temic scle­ro­sis in Q1 2021. First 3-pt dose co­hort suc­cess­ful­ly com­plet­ed in on­go­ing dose-es­ca­la­tion Ph 1 (an­ti-PD-L1/IL-15 fu­sion pro­tein) in pa­tients w me­tastat­ic or lo­cal­ly ad­vanced solid tu­mors; en­roll­ment on­go­ing in next dose lev­el. Cont­inu­ing IND-en­abling ac­tivi [more in­for­ma­tion]
KAHR
KAHR is de­vel­op­ing nov­el im­muno-on­col­o­gy fu­sion pro­teins. DSP107, is a CD47-41BB tar­get­ing com­pound aimed at tar­get­ing can­cer cells' in­nate de­fens­es and ac­ti­vat­ing lo­cal­ized re­sponse. Ac­ti­vat­ed path­ways in­clude in­nate and adap­tive im­mu­ni­ty. [more in­for­ma­tion]
Kaleido BioSciences [KLDO] $3 MM MCap
Har­ness­ing pro­pri­e­tary small molecule chem­istry plat­form to de­vel­op mi­cro­biome metabolic ther­a­pies (MMT) in in­di­ca­tions span­n­ing I-O, ni­tro­gen metabolism, metabolic dis­eas­es, and CNS. To­p­line da­ta ex­pect­ed in 1Q21 from mul­ti-cen­ter (K031) clin­i­cal study of KB109 in out­pa­tients with mild-to-mod­er­ate COVID-19 dis­ease and from study with Mas­sachusetts Gen­er­al Hos­pi­tal (K032). To­p­line da­ta from clin­i­cal study of KB295 in ap­prox­i­mate­ly 30 pa­tients with mild-to-mod­er­ate UC ex­pect­ed mid-2021, to­p­line da­ta from UNL [more in­for­ma­tion]
Keros Therapeutics [KROS] $626 MM MCap
A lead­er in un­der­s­tand­ing the role of the TGF-Be­ta fam­i­ly of pro­teins that is a mas­ter reg­u­la­tor of RBC and platelet pro­duc­tion as well as the growth, re­pair and main­te­nance of mus­cle and bone. Lead pro­tein ther­a­peu­tic prod­uct can­di­date, KER-050, is be­ing de­vel­oped for the treat­ment of cy­tope­nias, in­clud­ing ane­mia and throm­bo­cy­tope­nia, in pa­tients with myelodys­plas­tic syn­drome (MDS) and myelo­fi­bro­sis, with ad­di­tio­n­al da­ta ex­pect­ed from Part 1 of Ph 2 study in MDS be­ing pre­sent­ed at ASH 2021. [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) - whol­ly owned pre­clin­i­cal an­ti-VIS­TA (in­nate im­mune tar­get) anti­body re­pro­grams the tu­mor mi­croen­vi­ron­ment and is dif­fer­en­ti­at­ed from other im­munother­a­pies by block­ing sup­pres­sive cells in cold tu­mors. $360M+ deal with Ge­nen­tech for KCP506, Ph1 non-opi­oid for chron­ic pain. [more in­for­ma­tion]
Kintor Pharma [9939.HK]
Two Ph3s on­go­ing in Chi­na: Piv­o­tal monother­a­py and com­bo with abi­raterone and a Ph2 on­go­ing in US for mCR­PC (with breast and other AR-driv­en can­cers be­hind). Ad­di­tio­n­al pipe­line in­cludes a top­i­cal AR for alope­cia and ear­li­er-stage tar­gets in­clud­ing ALK-1 and hedge­hog. [more in­for­ma­tion]
Landos Biopharma [LABP] $32 MM MCap
Pipe­line tar­gets nov­el im­munometabolic path­ways, in­clud­ing LAN­CL2, NL­RX1 and PLXD­C2. Lead as­set omi­lan­cor is a nov­el, oral, gut-re­strict­ed small molecule ther­a­peu­tic can­di­date for the treat­ment of ul­cer­a­tive coli­tis (com­plet­ed Ph2), Crohn’s dis­ease (Ph2) and Eosinophil­ic Esophagi­tis that tar­gets the LAN­CL2 path­way [more in­for­ma­tion]
LianBio
Lian­Bio col­lab­o­rates with world-class part­n­ers across a di­verse ar­ray of ther­a­peu­tic and ge­o­graph­ic ar­eas to build out a pipe­line based on dis­ease rel­e­vance and the abil­i­ty to im­pact pa­tients with trans­for­ma­tive mech­anisms and pre­ci­sion-based ther­a­peu­tics. [more in­for­ma­tion]
Lineage Cell Therapeutics Inc. [LCTX] $214 MM MCap
Cell ther­a­py com­pany with 3 clin­i­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]
Marker Therapeutics [MRKR] $28 MM MCap
Fo­cused on de­vel­op­ing next-gen­er­a­tion T cell-based im­munother­a­pies for the treat­ment of he­ma­to­log­i­cal ma­lig­nan­cies and solid tu­mor in­di­ca­tions. Mark­er's cell ther­a­py tech­nol­o­gy is based on the se­lec­tive ex­pan­sion of non-en­gi­neered, tu­mor-spe­cif­ic T cells that rec­og­nize tu­mor as­so­ci­at­ed anti­gens and kill tu­mor cells ex­press­ing those tar­gets. [more in­for­ma­tion]
Maxcyte [MXCT:LN]
glob­al cell ther­a­py com­pany pro­vid­ing pro­pri­e­tary non-vi­ral cell en­gi­neer­ing tech­nol­o­gy for the next gen­er­a­tion of cell-based ther­a­pies in­clud­ing gene edit­ing and im­muno-on­col­o­gy. Max­Cyte may be seen as a play on the cell ther­a­py mar­ket with its blue chip client base. [more in­for­ma­tion]
MEI Pharma, Inc. [MEIP] $86 MM MCap
Broa­d­en­ing zan­delis­ib de­vel­op­ment ac­tiv­i­ty in­cludes ad­di­tion of margi­nal zone lym­pho­ma arm to TI­DAL to sup­port ex­pan­sion of an ac­cel­er­at­ed ap­pro­val strat­e­gy if suc­cess­ful, the ini­ti­a­tion of a Phase 3 study in se­cond line fol­lic­u­lar and margi­nal zone lym­pho­mas in mid-2021, and plans to sup­port se­lect in­vesti­ga­tor-ini­ti­at­ed trials, ini­tial­ly in first-line DL­B­CL. [more in­for­ma­tion]
Merus NV [MRUS] $966 MM MCap
Mul­ti­clon­ics® are man­u­fac­tured us­ing in­dus­try stan­dard pro­cess­es and have been ob­served in pre­clin­i­cal and clin­i­cal studies to have sev­er­al of the same fea­tures of con­ven­tio­n­al hu­man mon­o­clo­n­al anti­bodies, such as long half-life and low im­muno­genic­i­ty. [more in­for­ma­tion]
Minoryx Therapeutics
Oral PPARg ag­on­ist, lerigl­i­ta­zone, de­mon­s­trat­ed clin­i­cal ben­e­fit of sig­ni­f­i­cant­ly re­duc­ing pro­gres­sion of cere­bral le­sions and myelo­pa­thy symp­toms in piv­o­tal Phase 2/3 study re­sults in X-ALD pts w Adreno­myeloneu­ro­pa­thy (AMN), 6MWT end­point was not met; on­go­ing dis­cus­sions with reg­u­la­tors re: ap­pro­val. Phase 2 da­ta in Frie­drich’s Ataxia showed mo­d­u­la­tion of the Fra­taxin path­way and res­to­ra­tion of the bioen­er­get­ics de­fic­its in FR­DA pa­tients. VC in­ves­tors in­clude Kur­ma, Ysios, Fund+, Roche, Id­in­vest, etc [more in­for­ma­tion]
Monte Rosa Therapeutics [GLUE] $478 MM MCap
Next-gen­er­a­tion molec­u­lar glue-based tar­get­ed pro­tein degra­da­tion plat­form de­vel­op­ing small molecule ther­a­peu­tics that se­lec­tive­ly de­grade dis­ease-caus­ing pro­teins. Tar­get­ing the un­drug­gable pro­teome in on­col­o­gy and non-on­col­o­gy in­di­ca­tions via AI based de­gron pre­dic­tion. Lead pro­gram fo­cused on GSP­T1, a key reg­u­la­tor and vul­n­er­a­bil­i­ty of Myc-in­duced trans­la­tio­n­al ad­dic­tion. [more in­for­ma­tion]
Nanobiotix SA [NBTX] $141 MM MCap
Nano­bi­otix is a lead­ing, clin­i­cal-stage nanomedicine com­pany pi­oneer­ing new ap­proach­es to sig­ni­f­i­cant­ly change pa­tient out­comes by bring­ing nano­physics to the heart of the cell. Nano­bi­otix’s Im­muno-On­col­o­gy pro­gram has the po­ten­tial to bring a new di­men­sion to can­cer im­munother­a­pies. [more in­for­ma­tion]
Neoleukin Therapeutics [NLTX] $44 MM MCap
Its lead prod­uct can­di­date, NL-201, is a com­bined IL-2 and IL-15 ag­on­ist de­signed to im­prove tol­er­a­bil­i­ty and ac­tiv­i­ty by elim­i­nat­ing the al­pha re­cep­tor bind­ing in­ter­face. NL-201 is cur­rent­ly be­ing eval­u­at­ed in a Phase 1 clin­i­cal trial in pa­tients with re­lapsed or re­frac­to­ry can­cer and the com­pany is ex­pect­ing in­ter­im da­ta in 2022. [more in­for­ma­tion]
NexImmune, Inc. [NEXI] $38 MM MCap
Mul­ti-anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing di­rect­ly w tar­get­ed T cells. Two Ph 1's on­go­ing. [more in­for­ma­tion]
NorthSea Therapeutics
Fo­cused on de­vel­op­ing SE­FAs for the treat­ment of NASH and other metabolic di­s­or­ders. Lead prod­uct, icos­abu­tate has been found safe and ef­fec­tive in two pri­or phase 2 clin­i­cal studies for treat­ment of hy­per­trig­lyc­eridemia and mixed dys­lipi­demia and is cur­rent­ly in clin­i­cal de­vel­op­ment for NASH. The icos­abu­tate phase 2b ICO­NA NASH trial is sche­d­uled to read­out in the first quar­ter of 2023. Two ad­di­tio­n­al SE­FAs are in clin­i­cal de­vel­op­ment; SE­FA 1024 is in phase 1 to be de­vel­oped for dys­lipi­demia and SE­FA 6179, [more in­for­ma­tion]
NRx Pharmaceuticals, Inc. [NRXP] $39 MM MCap
Lead­ing Re­lief Ther­a­peu­tics Ph 2 trial of Avip­tadil to treat COVID-19 in­duced ARDS in the US. In Phase 3 with read­out ex­pect­ed mid-Jan­uary 2021. Al­so de­vel­op­ing first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. NRX-101 is in Ph 2b/3 de­vel­op­ment, (Break­through Desig­na­tion, SPA and Fast Track Desig­na­tion by FDA) for Se­vere Bipo­lar De­pres­sion in pts w Acute Sui­ci­dal Idea­tion and Be­havior. [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr965 MM MCap
De­vel­op­ing tar­get­ed ther­a­pies for pa­tients fac­ing hard-to-treat he­ma­to­log­i­cal dis­eas­es, with fo­cus on next gen­er­a­tion can­di­dates in­clud­ing OPD5 (Ph1) and OPD­C3 based on pro­pri­e­tary pep­tide drug con­ju­gate plat­form. EMA ap­pli­ca­tion pend­ing for melflufen (mel­pha­lan flufe­namide) in re­lapsed re­frac­to­ry mul­ti­ple myelo­ma; CHMP opinion ex­pect­ed in Q2 2022. [more in­for­ma­tion]
OncoResponse
In a broad strate­g­ic al­liance with MD An­der­son Can­cer Cen­ter, On­coRe­sponse de­ploys a pro­pri­e­tary B-cell dis­cov­ery plat­form to iden­ti­fy and de­vel­op nov­el ther­a­peu­tics tar­get­ing the tu­mor mi­croen­vi­ron­ment. [more in­for­ma­tion]
Oncorus [ONCR] $35 MM MCap
The com­pany's lead pro­gram ON­CR-177 is a Ph1 oHSV with com­ple­men­tary pay­loads (PD1, CCL4, IL12, FLT3, CT­LA4) to en­cour­age im­mune sti­m­u­la­tion, with read­out guid­ed for 2H21. [more in­for­ma­tion]
OnKure Therapeutics, Inc.
De­vel­op­ing epi­ge­net­ic can­cer ther­a­pies in­clud­ing HDAC in­hibi­tors. Lead as­set OKI-179 is a class 1 HDAC in­hibi­tor in Ph 1. [more in­for­ma­tion]
PharmaMar SA [PHM:ES]
Rev­enue gen­er­at­ing with marine-de­rived and nov­el MoA on­col­o­gy prod­ucts. Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized with di­rect sales-force in EU and part­n­er­ship in US with Janssen. Signed li­cens­ing agree­ment with Jazz Phar­ma for lur­binecte­din in the US - up­front pay­ment of $200M, $100mm on ap­pro­val and up to $550M sales mile­s­tones. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €495 MM MCap
re­cent in-li­cense from No­var­tis of late stage drug Le­ni­olis­ib for APDS (ul­tra-rare im­mun­od­e­fi­cien­cy con­di­tion), rhC1INH for new larg­er in­di­ca­tions in­clud­ing COVID-19, pre-eclamp­sia, AKI and ad­di­tio­n­al pipe­line prod­uct from tech­nol­o­gy plat­form: re­com­bi­nant al­pha-Glu­cosi­dase for Pompe dis­ease. [more in­for­ma­tion]
Photocure ASA [PHO:OS] NKr2,823 MM MCap
Lead prod­uct Hexvix®/Cysview® im­proves de­tec­tion of blad­der can­cer un­der blue light cys­tos­copy (BLC). Ap­proved in over 30 coun­tries, Hexvix®/Cysview® is di­rect­ly sold in the US and EU, and through world­wide part­n­er­ships. Pho­to­cure re­port­ed US$37.8M rev­enue in 2021 and ex­pects up to $250M from li­cense of non-core as­set CE­VI­RA® to Asieris. Head­quar­tered in Os­lo, Nor­way, Pho­to­cure is 20% owned by US in­ves­tors (sig­ni­f­i­cant in­crease over past few years) and com­mer­cial­ly fo­cused on US mar­ket. [more in­for­ma­tion]
Pliant Therapeutics, Inc. [PLRX] $277 MM MCap
Fo­cused on dis­cov­er­ing and de­vel­op­ing ther­a­pies for the treat­ment of fi­bro­sis. Pliant's lead prod­uct can­di­date, PLN-74809, is an oral small-molecule du­al se­lec­tive in­hibi­tor of avß6 and avß1 in­te­grins that is in de­vel­op­ment for the treat­ment of idio­path­ic pul­mo­nary fi­bro­sis, and pri­mary scle­ros­ing cholan­gi­tis. Se­cond prod­uct can­di­date, PLN-1474, is a small-molecule se­lec­tive in­hibi­tor of avß1 for the treat­ment of liv­er fi­bro­sis as­so­ci­at­ed with NASH, which Pliant has part­nered with No­var­tis. [more in­for­ma­tion]
PROSION
A phar­ma­ceu­ti­cal drug dis­cov­ery com­pany with pro­line de­rived mo­d­ules (ProMs) as the world’s first PRM struc­ture mim­ick­ing build­ing blocks. The com­pany de­vel­ops a new class of drugs and is able to ad­dress yet un­drug­gable con­sid­ered tar­gets that are re­lat­ed to vari­ous in­di­ca­tions. For its first of many use-cas­es, PRO­SION has al­ready shown a re­mark­able in vi­vo ef­fect of its ProM-based an­ti-me­tastat­ic in­hibi­tor – both in pan­cre­at­ic and breast can­cer xeno­graft ro­dent mod­els. [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] $411 MM MCap
Pro­pri­e­tary pep­tide tech­nol­o­gy plat­form to de­vel­op oral tar­get­ed ther­a­py-based drugs and in­jecta­bles for rare dis­eas­es. PTG-300 in­jectable hep­cidin mimet­ic Ph 2 trials on­go­ing in po­ly­cythemia ve­ra and hered­i­tary he­mochro­ma­to­sis; pos­i­tive up­dat­ed Ph 2 re­sults in PV pre­sent­ed at ASH 2020. PN-943 oral GI-re­strict­ed al­pha-4-be­ta-7 an­ta­g­on­ist Ph 2 in ul­cer­a­tive coli­tis study sites ac­ti­vat­ed; PTG-200, part­nered w/ Janssen, oral GI-re­strict­ed IL-23R an­ta­g­on­ist Ph 2 Crohn’s dis­ease study on­go­ing. [more in­for­ma­tion]
R2 Technologies
Head­quar­tered in Sil­i­con Val­ley, R2 fo­cus­es on the de­vel­op­ment and com­mer­cial­iza­tion of ground­break­ing tech­nolo­gies for aes­thet­ic providers and con­sumers. Based on the li­censed ex­clu­sive in­tel­lec­tu­al prop­er­ty from Mas­sachusetts Gen­er­al Hos­pi­tal to mo­d­u­late me­lanin pro­duc­tion, R2 Tech­nolo­gies was found­ed in 2014 by Pansend Life Sci­ences and Blos­som In­no­va­tions. [more in­for­ma­tion]
Rigel Pharmaceuticals [RIGL] $188 MM MCap
Fo­cused on he­ma­to­log­ic di­s­or­ders, can­cer, and rare im­mune dis­eas­es. Rigel's first FDA ap­proved prod­uct is TA­VALISSE® (fos­ta­ma­tinib di­s­odi­um hex­ahy­drate) tablets, the on­ly oral spleen ty­ro­sine ki­nase in­hibi­tor for the treat­ment of chron­ic im­mune throm­bo­cy­tope­nia. The Com­pany is al­so tar­get­ing SYK in Warm Anti­body AI­HA and COVID-19, in­ter­leukin re­cep­tor-as­so­ci­at­ed ki­nas­es 1&4 in on­col­o­gy and im­mune dis­eas­es, and re­cep­tor-in­ter­act­ing serine/thre­o­nine-pro­tein ki­nase 1 in CNS dis­eas­es. [more in­for­ma­tion]
Ryvu Therapeutics [RVU:WAR]
De­vel­op­er of tar­get­ed on­col­o­gy ther­a­pies in­clud­ing he­ma­tol­o­gy/solid tu­mors. RVU120 is whol­ly-owned first-in-class oral CD­K8/19 in­hibi­tor in Phase I for AML/MDS Small molecule, syn­thet­ic lethal­i­ty plat­form in pre-clin­i­cal de­vel­op­ment in­clud­ing nov­el tar­gets WRN and PRMT5. [more in­for­ma­tion]
Savara Inc. [SVRA] $172 MM MCap
Clin­i­cal-stage bio­phar­ma fo­cused on rare re­s­pi­ra­to­ry dis­eas­es; mol­gra­mos­tim, an in­haled gran­u­lo­cyte-macrophage colony-sti­m­u­lat­ing fac­tor (GM-CSF), is in Phase 3 de­vel­op­ment for the treat­ment of au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP); top-line da­ta from the dou­ble-blind pe­ri­od of the Com­pany’s Phase 3 trial (IM­PALA 2) is an­ti­ci­pat­ed at the end of 2Q 2024. [more in­for­ma­tion]
Secarna Pharmaceuticals GmbH
Se­car­na's unique­ly ef­fi­cient LNA­plus™ dis­cov­ery pro­cess is fu­eled by their pro­pri­e­tary and stream­lined Oli­go­fy­er™ bioin­for­mat­ics sys­tems large in-house cell li­brary and own in vit­ro screen­ing as­says. [more in­for­ma­tion]
Sol-Gel Technologies Ltd. [SLGL] $102 MM MCap
Com­mer­cial­iz­ing brand­ed gener­ic top­i­cal drug prod­ucts (skin dis­eas­es). Two pos­i­tive Phase 3 pro­grams, both with PD­U­FA dates in 2021: Ep­so­lay has po­ten­tial to be first FDA-ap­proved sin­gle-agent ben­zoyl per­oxide pre­scrip­tion drug prod­uct for rosacea (PD­U­FA date on April 26th). Twy­neo has po­ten­tial to be the first acne treat­ment that con­tains fixed dose com­bi­na­tion of BPO and treti­noin (PD­U­FA date on Au­gust 1st). [more in­for­ma­tion]
Sonnet Biotherapeutics, Inc. [SONN] $17 MM MCap
Uti­l­iz­ing a plat­form ap­proach to de­vel­op im­muno-on­col­o­gy ther­a­peu­tics fea­tur­ing a pro­pri­e­tary ful­ly hu­man Al­bu­min Bin­der ca­pa­ble of link­ing 1-2 dif­fer­ent ther­a­peu­tic tar­gets. Son­net's in­ter­leukin-based can­di­date has been shown to en­hance pK (up to 10 fold) and im­prove tu­mor de­liv­ery with an in­crease in in vi­vo ef­fi­ca­cy (30 fold) as de­mon­s­trat­ed in a mice tu­mor mod­el. [more in­for­ma­tion]
Spruce Biosciences [SPRB] $41 MM MCap
Fo­cused on de­vel­op­ing and com­mer­cial­iz­ing nov­el ther­a­pies for rare en­docrine di­s­or­ders. The com­pany’s lead prod­uct can­di­date, Til­dac­er­font, is cur­rent­ly be­ing eval­u­at­ed for the treat­ment of clas­sic adult con­geni­tal adre­nal hy­per­pla­sia (CAH), and in up­com­ing studies in pe­di­a­tric clas­sic CAH and Po­ly­cys­tic Ovary Syn­drome (PCOS). [more in­for­ma­tion]
sterna biologicals
By tar­get­ing tran­scrip­tion fac­tors that play a cen­tral role in reg­u­lat­ing Th1- and Th2-driv­en in­flam­ma­to­ry mech­anisms, the Com­pany’s pro­pri­e­tary DNAzyme-based drug can­di­dates can in­ter­vene with up­stream in­flam­ma­to­ry pro­cess­es to ad­dress re­lat­ed dis­eas­es more ef­fec­tive­ly. Ster­na cur­rent­ly has four pro­grams in phase 2 de­vel­op­ment. [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] $136 MM MCap
Rare dis­eas­es; Keveyis for PPP revs ~21.7M for 2019 and $26 - $27M for 2020. Re­cor­lev for en­doge­nous Cush­ing's syn­drome Ph 3 pub­lished with to­p­line place­bo-con­trolled Ph 3 3Q20. [more in­for­ma­tion]
Sutro Biopharma [STRO] $245 MM MCap
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and other com­plex bi­o­log­ics for can­cer. The com­pany’s FolR&al­pha;-tar­get­ing ADC (STRO-002) in ovarian can­cer is cur­rent­ly in Ph 1 with dose-ex­pan­sion da­ta ex­pect­ed in 2H 2021. En­roll­ment is on­go­ing for CD74-tar­get­ing ADC (STRO-001) in the Ph 1 dose-es­ca­la­tion in B-cell ma­lig­nan­cies. Sutro has three high val­ue col­lab­o­ra­tions with BMS, Mer­ck, and EMD Serono. [more in­for­ma­tion]
Syneos Health [SYNH] $7,480 MM MCap
Sy­neos Health® is an end-to-end, ful­ly in­te­grat­ed bio­phar­ma­ceu­ti­cal so­lu­tions com­pany that works dif­fer­ent­ly. At Sy­neos Health, all the dis­ci­p­lines in­volved in bring­ing new ther­a­pies to mar­ket, from clin­i­cal to com­mer­cial, work to­gether to cre­ate cus­tomer suc­cess. Our unique Bio­phar­ma­ceu­ti­cal Ac­cel­er­a­tion Mod­el de­liv­ers val­ue across the small to mid-size to large cus­tomer cont­in­u­um. [more in­for­ma­tion]
Teon Therapeutics
Pipe­line of next-gen­er­a­tion can­cer ther­a­peu­tics tar­get­ing GPCRs in­clud­ing a high­ly-spe­cif­ic A2B an­ta­g­on­ist and EP4 an­ta­g­on­ist, both slat­ed to en­ter Phase 1b trials in 2021. [more in­for­ma­tion]
Utility Therapeutics
UTIL­I­TY has re­ceived the FDA’s QDIP (qual­i­fied in­fec­tious dis­ease prod­uct) desig­na­tion for both prod­ucts and plans to file an NDA in 2021 for pive­me­cil­li­nam for the treat­ment of un­com­pli­cat­ed UTIs. Pivme­cil­li­nam is cur­rent­ly re­c­om­mend­ed as a first-line ther­a­py in the cur­rent ID­SA (In­fec­tious Dis­ease So­ci­e­ty of Amer­i­ca) treat­ment guide­lines for un­com­pli­cat­ed UTIs. [more in­for­ma­tion]
Vaccitech Plc [VACC] $195 MM MCap
Pro­pri­e­tary ChA­dOx (prime) and MVA (boost) tech­nol­o­gy plat­form in­duces CD8+ T cell and anti­body im­mune re­spons­es to treat and pre­vent in­fec­tious dis­eas­es and can­cer. Broad ther­a­peu­tic pipe­line. En­cour­ag­ing Ph1/2 in­ter­im ef­fi­ca­cy da­ta for VTP-300 (HBV func­tio­n­al cure) and VTP-200 (high-risk HPV ther­a­peu­tic) ef­fi­ca­cy da­ta ex­pect­ed 4Q2022. $15M roy­al­ty rev­enue dur­ing Q42021 from As­traZene­ca's com­mer­cial sales of Vaxzevria® (out-li­censed ChA­dOx COVID-19 vaccine) [more in­for­ma­tion]
Vericel Corporation [VCEL] $1,208 MM MCap
Ad­vanced cell ther­a­py; mar­ket­ing MA­CI (car­ti­lage re­pair) and Epi­cel (skin re­place­ment) in TAMs of $2b+. Q3 MA­CI and Epi­cel revs of $31.1m. Re­port­ed re­cord third quar­ter MA­CI rev­enue and to­tal rev­enues, and the se­cond high­est quar­ter­ly Epi­cel rev­enue in his­to­ry. Nexo­Brid PD­U­FA date of June 29, 2021. [more in­for­ma­tion]
Verrica Pharmaceuticals [VRCA] $60 MM MCap
A der­ma­tol­o­gy ther­a­peu­tics com­pany de­vel­op­ing med­i­ca­tions for skin dis­eas­es re­quir­ing med­i­cal in­ter­ven­tions. Ver­ri­ca's lead prod­uct can­di­date, VP-102, is a GMP-con­trolled for­mu­la­tion of can­tharidin de­liv­ered via a sin­gle-use ap­pli­ca­tor for the treat­ment of mol­lus­cum con­ta­gio­sum (mol­lus­cum), com­mon warts and ex­ter­nal geni­tal warts. The Com­pany is al­so de­vel­op­ing treat­ments for plan­tar warts (VP-103) and basal cell car­ci­no­ma (LTX-315). [more in­for­ma­tion]
Viela Bio [VIE] $2,913 MM MCap
UPLIN­ZA® (ine­bi­l­izumab, an­ti-CD19 mAb) on the mar­ket for the treat­ment of neu­romyeli­tis op­ti­ca spec­trum di­s­or­der (NMOSD). Ad­di­tio­n­al trials with ine­bi­l­izumab on­go­ing, in­clud­ing Ph 3 trials in myas­the­nia gravis and Ig­G4-re­lat­ed dis­ease. VIB7734, an­ti-ILT7 mAb, Ph 2 trial to ini­ti­ate in 1H21. Ph 2 trials on­go­ing for VIB4920 (An­ti-CD40L-Tn3 Fu­sion Pro­tein) in Sjo­gren's Syn­drome and kid­ney tran­s­plant re­jec­tion. [more in­for­ma­tion]
XOMA Corporation [XOMA] $238 MM MCap
Biotech roy­al­ty and mile­s­tone ag­gre­ga­tor with port­fo­lio of 70+ as­sets in >30 dis­closed in­di­ca­tions where R&D costs are borne by part­n­ers e.g. Roche's Faricimab (BLA filed for nAMD and DME 7/29/21) [more in­for­ma­tion]
Zentalis [ZNTL] $1,599 MM MCap
De­vel­op­ing best-in-class small molecule ther­a­peu­tics tar­get­ing fun­da­men­tal bi­o­log­i­cal can­cer path­ways. WEE1 in­hibi­tor for ad­vanced solid tu­mors cur­rent­ly in Ph 2. ZN-c5, an oral SERD for breast can­cer, ZN-d5, a BCL-2 in­hibi­tor for he­ma­to­log­ic ma­lig­nan­cies, and ZN-e4, an EGFR in­hibi­tor for NS­CLC. [more in­for­ma­tion]